Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00006454-199901000-00011PMID 9951979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rubella immunity. Defining the level of protective antibody.

  1996cited by this paper
• Adverse events associated with MMR vaccines in Japan

  1996cited by this paper
• Complications of mumps vaccines

  1995cited by this paper
• Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal

  1995cited by this paper
• A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.

  1995cited by this paper
• Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.

  1995cited by this paper
• The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

  1994cited by this paper
• The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates.

  1993cited by this paper
• Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children.

  1993cited by this paper
• Variations of nucleotide sequences and transcription of the SH gene among mumps virus strains.

  1991cited by this paper
• Risk of seizures after measles-mumps-rubella immunization.

  1991cited by this paper
• Pain and measles, mumps, and rubella vaccination.

  1991cited by this paper
• Duration of live measles vaccine-induced immunity.

  1990cited by this paper
• Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus.

  1990cited by this paper
• Measles antibody: reevaluation of protective titers.

  1990cited by this paper
• Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus.

  1990cited by this paper
• Measles active and passive immunity in a worldwide perspective.

  1989cited by this paper
• Long-term antibody response after measles vaccination in an isolated arctic society in Greenland.

  1986cited by this paper
• Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status

  1985cited by this paper
• Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines

  1984cited by this paper
• Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.

  1983cited by this paper
• Comparison of enzyme-linked immunosorbent assay for acute measles with hemagglutination inhibition complement fixation, and fluorescent-antibody methods

  1981cited by this paper
• Persistence of Antibody in Human Subjects for 7 to 10 Years following Administration of Combined Live Attenuated Measles, Mumps, and Rubella Virus Vaccines

  1980cited by this paper
• Evaluation of Enzyme-Linked Immunosorbent Assay (ELISA) for Mumps Virus Antibodies

  1979cited by this paper
• Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.

  1971cited by this paper
• Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation.

  1967cited by this paper
• STUDIES ON IMMUNITY TO MEASLES.

  1965cited by this paper
• Ender's live measles-virus vaccine with human immune globulin. II. Evaluation of efficacy.

  1962cited by this paper

• Immunogenicity and reactogenicity following MMR vaccination in 5–7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants

  2024cites this paper
• Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

  2022cites this paper
• Measles–Mumps–Rubella Vaccine

  2021cites this paper
• Immunogenicity and Safety of KM-248, a Combined Measles, Mumps, and Rubella vaccine, and the Noninferiority to a Measles Vaccine in Healthy Japanese Children; Phase 3 Randomized Multicenter Single-Blind Clinical Trial.

  2021cites this paper
• Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII

  2021cites this paper
• Climate Induced Virus Generated Communicable Diseases: Management Issues and Failures

  2021cites this paper
• Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines?

  2020cites this paper
• Vaccine failures: assessing yellow fever, measles, varicella, and mumps vaccines.

  2020cites this paper
• ADVERSE EVENTS FOLLOWING MEASLES-MUMPS-RUBELLA VACCINATION. A PROSPECTIVE OBSERVATIONAL STUDY

  2020cites this paper
• Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

  2019cites this paper
• Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.

  2018cites this paper
• 53 – Rubella Vaccines

  2018cites this paper
• 40 – Mumps Vaccines

  2018cites this paper
• Reply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review".

  2018cites this paper
• Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

  2018cites this paper
• Pain caused by measles, mumps, and rubella vaccines: A systematic literature review.

  2017cites this paper
• Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

  2017cites this paper
• Construction and Immunological Evaluation of Immunostimulatory Nanocomposites with Vaccine Potential

  2017cites this paper
• First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers

  2015cites this paper
• Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.

  2015cites this paper
• Sandfly (Diptera: Psychodidae: Phlebotominae) species diversity in an urban area of the municipality of Tapachula, Chiapas, Mexico

  2015cites this paper
• Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries

  2014cites this paper
• Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program

  2014cites this paper
• Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months

  2014cites this paper
• Perceived Risks from Live Viral Vaccines

  2013cites this paper
• Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2013cites this paper
• 22 – Mumps vaccine

  2013cites this paper
• A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.

  2013cites this paper
• Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

  2012cites this paper
• Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.

  2012cites this paper
• Acute Reactogenicity after Intramuscular Immunization with Recombinant Vesicular Stomatitis Virus Is Linked to Production of IL-1β

  2012cites this paper
• Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR)

  2012cites this paper
• Basi genetiche della risposta immune alle vaccinazioni.

  2012cites this paper
• Reappraisal of MMR vaccines currently used in Korea

  2011cites this paper
• Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Measles-mumps-rubella and Varicella Vaccines in Children Less Than 2 Years of Age

  2011cites this paper
• Which clinical signs predict severe illness in children less than 2 months of age in resource poor countries?

  2011cites this paper
• Adverse Effects of Vaccines

  2011cites this paper
• The immunological basis for immunization series: module 16: mumps

  2010cites this paper
• Rubulavirus: Mumps Virus

  2010cites this paper
• Reducing neonatal deaths.

  2010cites this paper
• Application of pharmacogenomics to vaccines.

  2009cites this paper
• A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.

  2009cites this paper
• Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

  2009cites this paper
• Adversomics: the emerging field of vaccine adverse event immunogenetics.

  2009cites this paper
• Personalized vaccines: the emerging field of vaccinomics

  2008cites this paper
• A multifactorial strategy of pain management is associated with less pain in scheduled vaccination of children. A study realized by family practitioners in 239 children aged 4-12 years old.

  2008cites this paper
• Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.

  2007cites this paper
• Safety and Immunogenicity of Early Vaccination with Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella (MMRV) Vaccine in Healthy Children from 9 Months of Age

  2007cites this paper
• The immunogenetics of smallpox vaccination.

  2007cites this paper
• Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial

  2007cites this paper
• Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.

  2007cites this paper
• Pain response to M-M-R vaccination in 4-6 year old children.

  2006cites this paper
• Mumps vaccine virus strains and aseptic meningitis.

  2006cites this paper
• Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.

  2006cites this paper
• THE ROLE OF PRE-GRAVIDITY MEASLES–RUBELLA IMMUNIZATION OF MOTHERS ON THE PASSIVE IMMUNITY AND IMMUNIZING EFFECT OF MMR VACCINE IN THEIR OFFSPRING

  2006cites this paper
• Fever following immunization

  2005cites this paper
• Review of the Varilrix™ varicella vaccine

  2005cites this paper
• The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study.

  2005cites this paper
• Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.

  2005cites this paper
• Open Randomized Trial Comparing the Immunogenicity and Safety of a New Measles-Mumps-Rubella Vaccine and a Licensed Vaccine in 12- to 24-Month-Old Children

  2005cites this paper
• Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants.

  2004cites this paper
• Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.

  2004cites this paper
• Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children.

  2004cites this paper
• Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children.

  2003cites this paper
• Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

  2003cites this paper
• Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.

  2003cites this paper
• Le phénomène de la douleur chez l'enfant

  2002cites this paper
• The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

  2002influential citation
• Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.

  2002cites this paper
• A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.

  2002cites this paper
• Surveillance of Measles-Mumps-Rubella Vaccine-Associated Aseptic Meningitis in Germany

  2002cites this paper
• Impact of osmolality on burning sensations during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults.

  2001cites this paper
• Immunogenicity and Reactogenicity of a New Measles, Mumps and Rubella Vaccine When Administered as a Second Dose at 12 y of Age

  2001cites this paper
• Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.

  2000cites this paper
• Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection.

  2000cites this paper
• Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children.

  2000cites this paper
• Evaluation of a Neonatal Rat Model for Prediction of Mumps Virus Neurovirulence in Humans

  2000cites this paper
• Comparability of M-M-R II and Priorix.

  1999cites this paper
• Author's concluding statement

  1999cites this paper
• Advance Publication by J-STAGE Japanese Journal of Infectious Diseases Immunogenicity and Safety of KM-248, a Combined Measles, Mumps, and Rubella vaccine, and the Noninferiority to a Measles Vaccine in Healthy Japanese Children; Phase 3 Randomized Multicenter Single-Blind Clinical Trial

  year unknowncites this paper